Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

Younes, Anas; H. Sehn, Laurie; Johnson, Peter; Luigi Zinzani, Pier; Hong, Xiaonan; Zhu, Jun; Patti, Caterina; Belada, David; Samoilova, Olga; Suh, Cheolwon; Leppä, Sirpa; Rai, Shinya; Turgut, Mehmet; Jurczak, Wojciech; C. Cheung, Matthew; Gurion, Ronit; Yeh, Su‐Peng; López‐Hernandez, Andrés; Dührsen, Ulrich; Thiéblemont, Catherine; Chiattone, Carlos; Balasubramanian, Sriram; Carey, Jodi; Liu, Grace; Martin Shreeve, S.; Sun, Steven; Hong Zhuang, Sen; Vermeulen, Jessica; M. Staudt, Louis; H. Wilson, Wyndham; behalf of the PHOENIX investigators, on

doi:10.1200/jco.18.02403

Public

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

Published in Journal of Clinical Oncology • Mar 22, 2019

Authors:

Anas Younes

Laurie H. Sehn

Peter Johnson

Abstract

PURPOSE Ibrutinib has shown activity in non–germinal center B-cell diffuse large B-cell lymphoma (DLBCL). This double-blind phase III study evaluated ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in untreated non–germinal center B-cell DLBCL. PATIEN...

Subject

Ibrutinib

Medicine

Vincristine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!